Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Altered Chemotherapy Sequencing in Rectal Cancer
NCT01302613Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2011
- Primary completion
- Nov 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, fluorouracil, folinic acid and oxaliplatin in rectal adenocarcinoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Surgical complications assessed by Clavien grading system at 90 days. Planned start Mar 2011; status: withdrawn.
02
Drugs
capecitabinefluorouracilfolinic acidoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT01302613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302613.